TrimRx

October 2026

1. 3. TrimRx publishes different starting figures on its homepage and in its terms. The terms describe a $199 first-month GLP-1 package and a $349 first-month compounded tirzepatide package, followed by $299 and $399 respectively; the homepage instead advertises GLP-1 from $179 and GLP-1 plus GIP from $259. Confirm the medication, initial charge and renewal amount before paying. Compounded packages include consultation, medication and shipping. Services are restricted to the 50 U.S. states; individual eligibility still requires clinical review.

September 2026

1. 4. The tirzepatide funnel was walked on 3 September 2026 to try to price this entry. TrimRx routes by asking "Which of these is most important to you? Affordability / Potency", and answering Potency carries you to its tirzepatide branch. The price never appears. The last screen before any figure asks for an email address and a telephone number and requires agreement "to be contacted as necessary by TrimRx and its medical partners" — so the tirzepatide price sits behind a contact wall and a consent, not behind a paywall. The walk was stopped there. The home page's "GLP-1 + GIP Starting at $259" remains the only public figure, and it names no billing period, so this entry still records no price.
2. 5. The intake reprices itself as you answer. On the medical-review screen it told us "You are a strong candidate for medical weight loss with a 94% chance of treatment success" and projected a goal date of "16.8 weeks" from a height and weight we chose arbitrarily — the same 94% figure an earlier walk recorded, against a different projection. A number that does not move when the inputs do is not a calculation about you.

September 2026

1. 6. TrimRx's home page offers two products under the headings “GLP-1” and “GLP-1 + GIP”, priced “Starting at $179” and “Starting at $259”, with “Get started for only $179” further down. None of those figures carries a billing period, so there is no price to record: a figure without its period cannot be compared with a monthly one, and giving it a period would be our claim rather than TrimRx's.
2. 7. TrimRx names no molecule, describing its products only as “GLP-1” and “GLP-1 + GIP”. A reference to GIP is not the same as naming tirzepatide, so no molecule is recorded.

August 2026

1. 8. TrimRx's plan grid rewards longer commitments with bigger savings cut into the sticker price at every tier. The cards read: "Monthly Plan · Billed monthly · Ships every month · Free shipping · The new you, delivered to your door monthly · 4 Week Supply · You are saving $120 on your first month · Select Plan · $299/month · PAY ONLY $179 LIMITED OFFER"; "3-Month Plan · Most Popular · Ships every 3 months · Free shipping · Receive your 3 month supply in a single shipment! · 12 Week Supply · Easy 0% Installments · You are saving $149 vs monthly · Select Plan · $249 $209/mo"; "You are saving $526 vs monthly · Select Plan · $211 $191/mo"; "12-Month Plan · Best Deal · Ships every 3 months · Commit to a year of progress and save on your new self · 48 Week Supply · You are saving $1,370 vs monthly · Select Plan · $184 $174/mo"
2. 9. TrimRx's checkout page for semaglutide stacks a savings claim, a countdown timer and a refund promise around one price. The order summary reads "Your Treatment Details · Medication: Semaglutide · Payment & delivery: Monthly · Total Savings: $120 · Shipping: FREE · Monthly Price: $299 $179/mo · Total if prescribed: $299 $179", followed by "You are saving $120 on your first month with your exclusive plan" and "CODE APPLIED: JOIN120". Urgency sits right next to it: "Only 23 discounts left. Yours is reserved for 7:23 minutes". The page also promises "Same Price. All Dosage Levels.", notes "Prescriptions are reviewed within 48 hours" and "Unlimited online support, 7 days a week", and closes with "100% refunded if not prescribed — Only charged if your prescription is approved."
3. 10. The scarcity mechanics, timed: "Only 33 discounts left" on the plan screen fell to 15 over roughly two minutes without any action from us, and the counter reading "12,199 patients chose this today" read "19,049" in the same session. A separate screen claimed a "94% chance of treatment success" and predicted our goal at "10.85 weeks", which two screens later had become "9.77 weeks".